SENSICARDIAC vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

SENSICARDIAC

by DIACOUSTIC MEDICAL (PTY)

EchoNext

by Pathway Labs

AI Verdict

SENSICARDIAC and EchoNext are adjacent tools in cardiac AI, both aiming to aid in early detection of heart conditions. SENSICARDIAC focuses on classifying heart murmurs using electronic stethoscopes, making it suitable for initial screenings and remote monitoring. EchoNext, conversely, analyzes standard ECGs to identify hidden structural heart disease, offering a different diagnostic approach for conditions like heart failure and valve disease.

Choose SENSICARDIAC if…

Choose SENSICARDIAC if your practice frequently utilizes electronic stethoscopes for patient examinations and requires real-time, AI-powered heart murmur classification to streamline diagnosis and reduce unnecessary specialist referrals. This tool is ideal for remote cardiac care scenarios and for physicians seeking detailed cardiac reports with guided auscultation.

View SENSICARDIAC →

Choose EchoNext if…

Choose EchoNext if your primary diagnostic tool for initial cardiac screening is the standard 12-lead ECG and you need an FDA-cleared AI solution to detect hidden structural heart diseases like heart failure, valve disease, or pulmonary hypertension. This tool is best suited for practices looking to enhance their clinical decision support for a broad range of patients, from major hospitals to community practices.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	SENSICARDIAC	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Cloud, Desktop (Windows)	Available through the OpenEvidence clinical decision support platform.
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

SENSICARDIAC

SENSICARDIAC emphasizes a guided auscultation process and has undergone usability validation in real-life clinical settings, with users scoring it highly (more than 4 out of 5). EchoNext, while integrated into a clinical decision support platform, does not provide specific details on its user interface or ease of use for clinicians, focusing more on its analytical capabilities. The direct mention of usability studies and positive user feedback for SENSICARDIAC gives it an edge in this dimension.

Clinical Value

EchoNext

EchoNext has strong clinical validation, with studies published in Nature and demonstrating higher accuracy in detecting structural heart problems than cardiologists, even those assisted by AI. It is also FDA-cleared for six indications, including heart failure and valve disease. SENSICARDIAC is FDA-cleared for heart murmur detection and classification, but its clinical validation details are less extensive in the provided information, primarily focusing on sensitivity and specificity relative to echocardiography for valvular heart disease.

Pricing & Value

EchoNext

EchoNext offers tiered pricing plans starting at $600/month, with clear details on implementation fees and annual discounts, providing transparency and allowing potential customers to estimate costs. SENSICARDIAC's pricing is not publicly available, requiring direct contact for information, which makes it less transparent and harder to assess its value proposition without further inquiry.

Enterprise Readiness

EchoNext

EchoNext is available through the OpenEvidence clinical decision support platform, which is used by 650,000 U.S. physicians, indicating a strong existing infrastructure for deployment and integration within enterprise healthcare systems. SENSICARDIAC is cloud-based and offers desktop deployment, but lacks specific information about its integration capabilities with broader enterprise systems or its current adoption scale within large organizations.

Innovation

EchoNext

EchoNext is described as the world's first FDA-approved AI detection tool that analyzes ECGs to detect high-risk structural heart disease, representing a novel approach to screening for conditions traditionally diagnosed with more expensive tests like echocardiograms. SENSICARDIAC offers AI-powered heart murmur detection and classification, which is valuable but builds upon existing auscultation methods rather than introducing a fundamentally new screening paradigm.

Support & Docs

Tie

Neither tool provides explicit details regarding their customer support channels, service level agreements, or the availability of comprehensive documentation. While both are FDA-cleared and imply professional standards, there is insufficient information to differentiate them on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	SENSICARDIAC	EchoNext
Name	SENSICARDIAC	EchoNext
Company	DIACOUSTIC MEDICAL (PTY)	Pathway Labs
Description	AI-powered, cloud-based heart murmur detection service that integrates with electronic stethoscopes to classify murmurs as pathological or physiological, aiding physicians in diagnosis and reducing unnecessary referrals.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features	AI-powered heart murmur detection; Cloud-based service; Integration with electronic stethoscopes (e.g., 3M Littmannu00ae 3200); Analysis against a large validated database of pathological heart murmurs; Classification of murmurs (Class I: dangerous pathological, Class III: innocent physiological); Detailed cardiac reports (downloadable PDFs, visualization, S1/S2 indicators); Guided auscultation process; Real-time analysis.	AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support.
Specialties	Cardiology, Internal Medicine, Pediatrics	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring SENSICARDIAC and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

SENSICARDIAC integrates with electronic stethoscopes and provides downloadable PDF cardiac reports, suggesting a workflow where recordings are taken and then reports are generated for review. EchoNext is available through the OpenEvidence clinical decision support platform, which is used by many physicians, implying a more direct integration into existing clinical decision-making processes and potentially EHRs through that platform.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

SENSICARDIAC classifies murmurs as pathological or physiological, with one study on a similar device reporting u226590% sensitivity, specificity, and efficiency for correct diagnosis in children with heart disease. EchoNext, an AI-powered ECG model, has demonstrated high accuracy in detecting structural heart disease, with an AUROC of 85.2% in internal tests and 78-80% in external validation, and it outperformed cardiologists in studies, achieving 77% accuracy compared to 64% for cardiologists alone.

What is the learning curve for physicians to effectively use each tool?

SENSICARDIAC features a guided auscultation process and real-time analysis, which could suggest a relatively straightforward learning curve for physicians familiar with electronic stethoscopes. EchoNext analyzes standard 12-lead ECGs, a routine test, and its integration with a clinical decision support platform like OpenEvidence could mean that physicians primarily interact with its output rather than a complex new interface, potentially simplifying its adoption.

What kind of customer support and resources are available for physicians using these tools?

SENSICARDIAC's description mentions it as a service, implying some level of support, but specific details on support quality or resources are not provided. EchoNext is offered by Pathway Labs, which is expanding its clinical and commercial teams, and its partnership with OpenEvidence suggests support may be available through that platform.

What are the audit-trail features of each tool, and how do they support clinical documentation and accountability?

The provided information does not explicitly detail the audit-trail features for either SENSICARDIAC or EchoNext. However, SENSICARDIAC generates detailed cardiac reports in downloadable PDF format, which could serve as part of a patient's record. EchoNext's integration with a clinical decision support platform suggests its outputs would likely be incorporated into clinical documentation, but specific audit functionalities are not described.

How do these tools facilitate multi-site rollouts, and what considerations should be made for larger healthcare systems?

SENSICARDIAC is a cloud-based service and offers user management and billing, which could support multi-site deployment, and it is available for white labeling for telehealth integrators. EchoNext has demonstrated consistent performance across diverse patient demographics, clinical contexts, and numerous hospitals in studies, and its deployment through the OpenEvidence platform aims for broad access from major hospitals to community practices, indicating readiness for multi-site rollouts.

In what clinical contexts would each tool be most beneficial for a physician, considering their distinct functionalities?

SENSICARDIAC is most beneficial for physicians evaluating cardiac murmurs, particularly in primary care, urgent care, or during routine physicals, to differentiate between pathological and physiological murmurs and reduce unnecessary referrals. EchoNext is ideal for early detection of hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, using standard ECGs, which can help identify high-risk patients who need further echocardiographic evaluation, potentially transforming cardiac screening.